Systematic (IUPAC) name
17-(tert-butylcarbamoyl)androsta-3,5-diene-3-carboxylic acid
Clinical data
Legal status
  • Non-regulated
Routes Oral
Pharmacokinetic data
Bioavailability 93%[1]
Half-life 26 hours[1]
CAS number
ATC code None
Chemical data
Formula C25H37NO3 
Mol. mass 399.566 g/mol

Epristeride (SKF-105,657, ONO-9302) is a selective, transition state, non-competitive inhibitor of the type II isoform of the enzyme 5α-reductase,[2][3] similarly to finasteride and turosteride. It was under development for the treatment of benign prostatic hyperplasia and acne vulgaris by SmithKline Beecham (now GlaxoSmithKline), and reached phase III clinical trials in the United States, United Kingdom, and Japan,[2] but ultimately was never marketed.

See also


  1. ^ a b Benincosa LJ, Audet PR, Lundberg D, Zariffa N, Jorkasky DK (April 1996). "Pharmacokinetics and absolute bioavailability of epristeride in healthy male subjects". Biopharmaceutics & Drug Disposition 17 (3): 249–58.  
  2. ^ a b Hedge SS (May 1998). "Epristeride SmithKline Beecham". IDrugs : the Investigational Drugs Journal 1 (1): 152–7.  
  3. ^ Berthaut I, Mestayer C, Portois MC, Cussenot O, Mowszowicz I (August 1997). "Pharmacological and molecular evidence for the expression of the two steroid 5 alpha-reductase isozymes in normal and hyperplastic human prostatic cells in culture". The Prostate 32 (3): 155–63.